Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Becton, Dickinson stock gained 2.56 percent on September 25

Earnings report AI-generated analysis

πŸ“ˆ BDX stock gained 2.56% on September 25, closing at $183.82 after beating Q3 revenue and EPS estimates.

πŸ’° Q3 fiscal 2026 revenue reached $4.98 billion, representing a 5.4% increase from the prior-year quarter.

πŸ“Š Adjusted EPS for the quarter came in at $3.23, exceeding the consensus estimate of $3.14 by $0.09.

🎯 Analysts maintain an average 12-month price target of $187.67, indicating potential upside from current levels.

πŸ“… The company provided fiscal 2026 adjusted EPS guidance between $12.62 and $12.72, aligning with market consensus.

πŸ₯ BDX operates in the Healthcare sector focusing on Medical Instruments and Supplies with a global presence.

πŸ“‰ The stock is currently trading 4.79% below its 52-week high of $193.07 as of September 25, 2026.

Bullish Signals
  • Becton, Dickinson and Company reported Q3 fiscal 2026 revenue of $4.98 billion, beating the analyst consensus estimate of $4.89 billion.
  • The company delivered adjusted EPS of $3.23 for the quarter, surpassing the expected $3.14 by $0.09.
  • Revenue grew 5.4% year-over-year, demonstrating solid top-line growth in the medical technology sector.
  • Analysts have set an average 12-month price target of $187.67, which is approximately 2.09% above the current trading price.
Risk Factors
  • The stock is currently trading 4.79% below its 52-week high of $193.07, indicating some downside from recent peaks.
  • The consensus analyst rating remains Hold, with a balanced distribution of eight Buy, eight Hold, and one Sell ratings.
Full Analysis
Becton, Dickinson and Company (BDX) shares rose 2.56% to close at $183.82 on September 25, 2026, driven by a strong quarterly earnings beat. The medical technology firm reported Q3 fiscal 2026 revenue of $4.98 billion, surpassing the consensus estimate of $4.89 billion, while adjusted earnings per share reached $3.23 against a forecast of $3.14. The company's financial performance highlighted robust growth with revenue increasing 5.4% year-over-year. Analysts maintain an average price target of $187.67, suggesting potential upside from current levels, though the consensus rating remains Hold with a balanced mix of Buy and Sell recommendations. The stock trades at a market capitalization of approximately $50.6 billion. Looking ahead, BDX has provided fiscal 2026 adjusted EPS guidance ranging between $12.62 and $12.72, which aligns closely with the current analyst consensus of $12.67. The next earnings report is scheduled for November 5, 2026, providing investors with a clear checkpoint to monitor future performance trends in the medical instruments sector.